A Phase 2 Proof‐of‐Concept, Randomized, Placebo‐Controlled Trial of CX‐8998 in Essential Tremor

BACKGROUND: Available essential tremor (ET) therapies have limitations. OBJECTIVES: The objective of this study was to evaluate CX‐8998, a selective T‐type calcium channel modulator, in essential tremor. METHODS: Patients 18–75 years old with moderate to severe essential tremor were randomized 1:1 t...

Descripción completa

Detalles Bibliográficos
Autores principales: Papapetropoulos, Spyros, Lee, Margaret S., Versavel, Stacey, Newbold, Evan, Jinnah, Hyder A., Pahwa, Rajesh, Lyons, Kelly E., Elble, Rodger, Ondo, William, Zesiewicz, Theresa, Hedera, Peter, Handforth, Adrian, Elder, Jenna, Versavel, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Regular Issue Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451783/
https://www.ncbi.nlm.nih.gov/pubmed/33764619
http://dx.doi.org/10.1002/mds.28584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451783/
https://www.ncbi.nlm.nih.gov/pubmed/33764619
http://dx.doi.org/10.1002/mds.28584

Ejemplares similares